MADRIGAL PHARMACEUTICALS
Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The Company is targeting treatment of both niche and prevalent indications, including diabetes, dyslipidemia and cardiovascular disease.
MADRIGAL PHARMACEUTICALS
Industry:
Biotechnology Medical Device Pharmaceutical
Founded:
2011-01-01
Address:
Washington, Pennsylvania, United States
Country:
United States
Website Url:
http://www.madrigalpharma.com
Total Employee:
1+
Status:
Active
Contact:
(267) 327-4445
Email Addresses:
[email protected]
Total Funding:
288.38 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Tag Manager WordPress Domain Not Resolving Wordpress Plugins Nginx IPv6
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Madrigal Pharmaceuticals
Bay City Capital
Bay City Capital investment in Post-IPO Equity - Madrigal Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-10 | Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer |
Official Site Inspections
http://www.madrigalpharma.com Semrush global rank: 2.78 M Semrush visits lastest month: 5.83 K
- Host name: 104.26.6.220
- IP address: 104.26.6.220
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Madrigal Pharmaceuticals" on Search Engine
Madrigal Pharmaceuticals – Transforming the Treatment of Non …
May 7, 2024 Madrigal is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH).See details»
About Us – Madrigal Pharmaceuticals
Madrigal is a biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH).See details»
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra ...
Mar 14, 2024 Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffraâ„¢ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis. PDF Version. Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as …See details»
Leadership – Madrigal Pharmaceuticals
Madrigal’s leadership team is comprised of individuals with proven track records developing multiple FDA-approved medicines and expertise in building and leading successful biopharmaceutical companies. BILL SIBOLD. Chief Executive Officer. Mr. Sibold has more than 30 years of experience in the biopharmaceutical industry.See details»
Madrigal Pharmaceuticals Announces U.S. Availability of …
Apr 9, 2024 Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of …See details»
Overview | Madrigal Pharmaceuticals.
Apr 24, 2024 Madrigal is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH). Our first therapy was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being ...See details»
Madrigal, eyeing a NASH drug launch, nabs Dupixent vet as CCO
Nov 13, 2023 Madrigal Pharmaceuticals has hired Carole Huntsman as its new chief commercial officer to help the biotech navigate a new and potentially tricky launch in nonalcoholic steatohepatitis (NASH)....See details»
FDA approves first drug for common form of liver inflammation
Mar 14, 2024 From Madrigal Pharmaceuticals. CNN — The US Food and Drug Administration has approved the first medication for a common form of liver inflammation called nonalcoholic steatohepatitis, or NASH,...See details»
Madrigal's stock shaken by CEO change up ahead of NASH …
Sep 11, 2023 Madrigal Pharmaceuticals’ CEO Paul Friedman, M.D., is stepping aside so Sanofi’s Bill Sibold can take the reins ahead of a possible FDA greenlight for what would be the first treatment...See details»
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive ...
Sep 11, 2023 Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist …See details»
Madrigal Pharmaceuticals Presents New Data from the Phase 3 …
CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced new data from the Phase 3 MAESTRO-NASH trial demonstrating broad treatment effects of …See details»
Madrigal Pharmaceuticals To Announce Topline Results from the …
Dec 18, 2022 Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet...See details»
Board Of Directors – Madrigal Pharmaceuticals
Dr. Craves co-founded and served as Chairman of the Board of Private Madrigal, a privately-held biopharmaceutical company, from its inception in September 2011 through the Merger involving Synta, in July of 2016.See details»
Madrigal Pharmaceuticals Provides Corporate Updates and …
CONSHOHOCKEN, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of recent corporate accomplishments, previews new Phase 3 MAESTRO study …See details»
Madrigal Pharmaceuticals, Inc. (MDGL) - Yahoo Finance
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United...See details»
Madrigal Pharmaceuticals - Crunchbase Company Profile & Funding
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cardiovascular-metabolic diseases. The company targets the treatment of both niche and prevalent indications, including diabetes, dyslipidemia, and cardiovascular disease.See details»
Madrigal Pharmaceuticals - Funding, Financials, Valuation
Madrigal Pharmaceuticals is a biopharmaceutical company developing therapeutics for the treatment of cardiovascular-metabolic diseases.See details»
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief
Sep 11, 2023 Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet...See details»
Madrigal Pharmaceuticals - Recent News & Activity - Crunchbase
Apr 3, 2024 Organization. Madrigal Pharmaceuticals. Connect to CRM. Go back to Madrigal Pharmaceuticals's Summary. Recent News & Activity. News • Apr 3, 2024. Globe Newswire — Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 (c) (4) News • Mar 29, 2024.See details»
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief …
Feb 28, 2024 Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once-daily, oral, liver-directed THR-β agonist designed to target key …See details»